Clinical Trial Update: Mechanisms of EPO-induced Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 study on the mechanisms of erythropoietin-induced hypertension in chronic kidney disease was terminated, with results posted on 2025-12-15.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease
• Hypertension

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Chronic Kidney Disease, Blood Pressure | Phase 2 | Status: TERMINATED | Results posted: 2025-12-15